NCT05681819已完成1 期
A Phase Ib, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- To assess the number of patients with adverse events (AEs)
研究概览
简要总结
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥55and ≤85 on the date of signing the informed consent, males or females;
- •BMI≥19kg/m2 and ≤32 kg/m2, weight ≥45 kg 且≤100 kg at screening or baseline；
- •must meet the diagnostic criteria for MCI due to AD or mild AD;
- •The total score of HAMD-17 should be ≤10 scores at screening and baseline;
- •The score of Hachinski ischemic scale should be ≤4 scores at screening and baseline;
- •Qualitative amyloid PET scan results from the central laboratory confirmed the presence of pathological changes in AD;
- •Agreed to test ApoE genotype;
- •Have a stable caregiver; where symptomatic drugs for AD is used, they must be stable for at least 3 months prior to the baseline visit;
排除标准
- •Cognitive impairment of subjects due to other medical or neurological factors (other than AD);
- •History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past year;
- •Any psychiatric diagnosis that may interfere with the subject's cognitive assessment;
- •Cannot tolerate MRI or has contraindications to MRI, has significant lesions shown on MRI during screening, or has other conditions that the investigator believes may bring a significant risk to the subject;
- •Suspected allergy to Aβ antibody drugs and excipients.
- •Patients who had severe trauma or had undergone surgery within 6 months prior to screening, or were scheduled to undergo surgery during the trial;
- •History of moderate (3b) or severe renal failure or insufficiency;
- •Uncontrolled hypertension: systolic blood pressure > 160mmHg and diastolic blood pressure >100mmHg in supine position during screening or baseline;
- •12-lead ECG showed QTcF >450ms for male and >470ms for female during screening;
- •History of hypoglycemic coma or uncontrolled diabetes 6 months prior to the screening period;
- •Thyroid dysfunction；
- •Had unstable or clinically significant cardiovascular disease within 1 year prior to the screening period, had or currently has atrial fibrillation;
- •History of malignancy within 5 years prior to screening;
- •Patients with clinically significant systemic immunosuppression due to the persistent effects of immunosuppressive drugs;
- •Human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody and hepatitis C virus antibody (HCV-Ab) were positive during screening.Hepatitis B active subjects [Hepatitis B virus surface antigen (HBsAg) positive with HBV DNA > upper limit of normal]
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 3 times ULN, or total bilirubin exceeding 2 times ULN
- •Folic acid or vitamin B12 below the lower limit of normal
- •coagulation disorders
- •According to the investigators, the subjects were suicidal or had committed suicidal behavior in the six months before the screening period;
- •Severe visual or hearing impairment, unable to cooperate with the completion of the scale;
- •A woman who is pregnant, or a woman of childbearing potential whose pregnancy test results are positive, or who is breastfeeding; or has a plan to have a child, unwilling or unable to take effective contraceptive measures within 30 days prior to the screening period or six months after the last use of the investigational drug.
- •History of drug abuse or addiction;
- •Three months prior to the randomization period or planned to use dual antiplatelet or anticoagulant drugs during the trial;
- •Received any passive immunotherapy or other long-acting biologics used to prevent or delay cognitive decline within 1 year prior to screening;
- •Investigators and relevant staff of the research Centre or others directly involved in programme implementation;
- •The investigator considers that there are any circumstances that would cause the subject to be unable to complete the study or pose a significant risk to the subject or other factors that would interfere with the subject's ability to complete the study evaluation.
研究组 & 干预措施
SHR-1707
Experimental
Up to4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 injection
干预措施: SHR-1707 (Drug)
SHR-1707 placebo
Placebo Comparator
Up to 4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 placebo injection
干预措施: SHR-1707 placebo (Drug)
结局指标
主要结局
To assess the number of patients with adverse events (AEs)
时间窗: week 26
To assess the number of patients with clinically significant change in physical examination,
时间窗: week 26
To assess the number of patients with clinically significant change from baseline in vital signs values,
时间窗: week 26
To assess the number of patients with clinically significant change from baseline in laboratory examination,
时间窗: week 26
To assess the number of patients with clinically significant change from baseline in 12-ECG values,
时间窗: week 26
To assess the number of patients with clinically significant change in brain MRI (cerebral edema, microbleeding, etc.)
时间窗: week 26
次要结局
- To assess the ADA(week26)
- To assess the number of patients with adverse events (AEs),(week 52\week78)
- To assess the change from baseline in Brain Amyloid Plaque Deposition as measured by Aβ PET(week26/52/78)
- To assess the number of patients with clinically significant change from baseline in vital signs values,(week 52\week78)
- To assess the number of patients with clinically significant change in physical examination,(week 52\week78)
- To assess the number of patients with clinically significant change from baseline in laboratory examination,(week 52\week78)
- To assess the number of patients with clinically significant change from baseline in 12-ECG values,(week 52\week78)
- To assess the number of patients with clinically significant change in Head brain MRI (cerebral edema, microbleeding, etc.),(week 52\week78)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease PatientsAlzheimer's DiseaseNCT06199037Shanghai Hengrui Pharmaceutical Co., Ltd.45
已完成
1 期
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseAlzheimer's Disease (AD)NCT06114745Atridia Pty Ltd.2
已完成
2 期
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeAsthma With Eosinophilic PhenotypeNCT05522439Jiangsu HengRui Medicine Co., Ltd.85
进行中（未招募）
3 期
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaAsthma With Eosinophilic PhenotypeNCT06653322Guangdong Hengrui Pharmaceutical Co., Ltd401
招募中
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal WomenOsteoporosisNCT05930704Suzhou Suncadia Biopharmaceuticals Co., Ltd.45